Astellas’ Veozah Is First-In-Class Treatment For Vasomotor Symptoms
Executive Summary
Veozah received approval from the US FDA for a common symptom of menopause, a therapeutic area that has lacked pharmaceutical advancements.
You may also be interested in...
Bayer Ready To File Elinzanetant After It Clears Third Phase III Hurdle
Bayer will submit its non-hormonal treatment for vasomotor symptoms associated with menopause for approvals this year, still eyeing €1bn-plus in peak sales despite a rival’s slow start.
Bayer Hot On The Trail Of Astellas As Menopause Drug Flies In Phase III
Astellas’s fezolinetant is already on the market but Bayer is confident its non-hormonal menopause drug elinzanetant will be able to catch up on the back of demonstrating significant reductions in the frequency and severity of hot flashes in a couple of Phase III trials.
Organon Widens Business Development Lens To Maintain Women’s Health Focus
Organon has not strayed from its women’s health path, but is entering into earlier deals and considering technologies beyond therapeutics, while advocating increased investment in the field.